Earnings report for Neovasc Inc. (NASDAQ:NVCN) is expected on March, 27., as reported by Faxor. Analysts have anticipation on stock’s earnings per share of $-0.13. That’s up 93.50 % from last year’s $-2 earnings per share. Last quarter $-0.61 earnings per share was reported. Analysts sees -78.69 % EPS growth this quarter. Ticker’s shares touched $0.5406 during the last trading session after 7.59% change.Neovasc Inc. has volume of 1.09 million shares. Since March 6, 2018 NVCN has declined 97.60% and is downtrending. NVCN underperformed the S&P 500 by 101.97%.

Neovasc Inc., a specialty medical device company, develops, makes, and markets cardiovascular devices worldwide.The company has $26.74 million market cap. The Company’s products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina.Currently it has negative earnings. The firm also provides Peripatch biological tissue products that are used as components in third-party medical products, such as transcatheter heart valves for industry partners and other customers.

For more Neovasc Inc. (NASDAQ:NVCN) news published recently go to: Seekingalpha.com, Seekingalpha.com, Prnewswire.com, Nasdaq.com or Seekingalpha.com. The titles are as follows: “Neovasc readies stock offering; shares down 12% after hours – Seeking Alpha” published on February 25, 2019, “Neovasc up 24% premarket – Seeking Alpha” on October 23, 2018, “Neovasc Provides Corporate Update – PRNewswire” with a publish date: February 20, 2019, “US Futures Ease Ahead of Data Deluge, Powell Speech – Nasdaq” and the last “Neovasc receives nasdaq notification regarding minimum market value deficiency – Seeking Alpha” with publication date: January 04, 2019.